Adam Elsesser

CEO, President, Chairman of the Board at Penumbra

Board

Since June 2004

Age

62 years

Education

Holds a B.A. from Stanford University and a J.D. from Hastings College of the Law.

Tenure

Co-founded PEN in June 2004, has served as CEO and a board member since its inception, was appointed Chairman of the Board in January 2015, and held the presidency from January 2015 until August 2019, resuming it in May 2020.

Also at Penumbra

Johanna Roberts

EVP, General Counsel, and Secretary

Lambert Shiu

Chief Accounting Officer (CAO)

Maggie Yuen

Chief Financial Officer (CFO)

About

Adam Elsesser co-founded PEN in June 2004 and has since been a pivotal force in the company’s growth and strategic direction. His tenure has been marked by sustained leadership as he took on multiple key roles, including serving as CEO since the company’s inception and being a long-standing board member. His transition into the role of Chairman in January 2015 further solidified his influence in steering the company forward.

Prior to founding PEN, he held significant executive roles in the medical device industry. As the CEO of SMART Therapeutics, Inc. from 2000 to 2002 and later as President of SMART Therapeutics within Boston Scientific from 2002 to 2005, he demonstrated his capability in leading and commercializing innovative medical devices.

Before his career in the medical device field, he was a partner at the law firm Shartsis Friese LLP, showcasing his diverse professional background. This blend of legal acumen and executive leadership has enriched his approach to guiding high-stakes business decisions at PEN.

Through his comprehensive experience in both the legal and medical device sectors, his leadership continues to shape PEN's competitive strategy and market positioning, blending industry expertise with formidable business insights.

$PEN Performance Under Adam Elsesser

Past Roles

Organization	Role	Date Range	Details
Penumbra	President	January 2015 – August 2019	Former term; currently holds the role again since May 2020
Penumbra	Board Member	June 2004 – January 2015	Consistently served as a board member from the company’s founding until executive promotions
SMART Therapeutics, Inc.	Chief Executive Officer	2000 – 2002	Led a medical device company focused on neuro-intervention
SMART Therapeutics, Inc. (under Boston Scientific Corporation)	President	2002 – 2005	Served in a post-acquisition role following SMART Therapeutics’ acquisition by Boston Scientific Corporation
Shartsis Friese LLP	Partner	N/A	Held the role prior to entering the medical device industry

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$600,000	Annual	Unchanged since March 2021
All Other Compensation	$1,620	Annual	Includes life insurance and short-term and/or long-term disability insurance premium payments

Performance Compensation

Data from FY 2023

No information available on performance compensation for 2023